You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
阿里健康(00241.HK)與信達生物(01801.HK)達成疾病管理及數字化營銷戰略合作
阿里健康(00241.HK)與信達生物(01801.HK)簽署戰略合作協議,雙方計劃在診後疾病管理、供應鏈、數字化營銷等領域開展深度合作,爲消費者提供普惠可及的醫藥和健康管理服務。 今年以來,雙方已在科學減重領域達成合作,信達生物新一代減重藥物瑪仕度(月太)注射液獲批上市後,即在阿里健康平臺提供預約服務。未來,阿里健康與信達生物將聯合研發基於家庭場景的診後疾病管理系統,包括用藥指導、生活方式諮詢、陪伴式服務,爲患者提供全週期健康管理解決方案。阿里健康亦將提供訂製化供應鏈解決方案,確保藥品儲存合規,安全有效送到用戶手中。 信達生物創始人、董事會主席、首席執行官俞德超表示,信達生物與阿里健康在醫藥創新和醫療普惠具有高度互補性和協同潛力,期待共同探索創新醫療解決方案。阿里健康執行董事兼首席執行官沈滌凡指,期待未來與信達生物共同探索在腫瘤、眼病等更多疾病領域的合作。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account